COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy & Safety of Belantamab Mafodotin in Combination with Pomalidomide & Dex (B-Pd) versus Pomalidomide plus Bortezomib & Dex (PVd) in Participants with Relapsed/Refractory Multiple Myeloma

Protocol No
GSK-207499-DREAMM-08
Principal Investigator
Binod Dhakal
Phase
III
Summary
This research study is being done to learn more about multiple myeloma (MM) and if the study drug called Belantamab Mafodotin can improve MM in participants who have already received at least one other treatment and whose MM has worsened
Description
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Participating Institutions
Froedtert Hospital
Status
SRC APPROVAL